Project Grant HT94252411013
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$878K
Federal Agency
Defense Health Agency
Federal Grant Program
12.007
Assistance Type
Project Grant
Place of Performance
New York, NY 10022, USA
Similar Awards
The federal Project Grant award of $1,356,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) aims to support the "Restoration of Clear Cell Renal Cell Carcinoma Tumorigenicity by Cell Reprogramming" research at Weill Medical College of Cornell University. The award, which runs from November 1, 2024 to October 31, 2028, will fund advanced biomedical research focused on transforming healthcare for military service members and the...
This Project Grant award of $988,740.00 from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by Weill Medical College of Cornell University to develop genomically informed morphological stromal signatures to predict lethal prostate cancer. The 3-year award, which commenced on June 15, 2025, aims to transform healthcare for military service members and the broader public by advancing disease...
The federal Project Grant award of $312,610.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award is to support research on the "ROLE OF FUNCTIONAL FACTORS IN AR REPROGRAMMING AND PROGRESSION OF PROSTATE CANCER". The award was made to Weill Medical College of Cornell University, a prominent academic medical institution, on September 30, 2024, with a performance period ending on September 29,...
The U.S. Defense Health Agency awarded a $1,522,278 Project Grant to Weill Medical College of Cornell University on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a research project titled "Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging Data." The project aims to advance scientific understanding and improve treatment of bone metastasis in prostate cancer patients...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,518,817.00 to the Weill Medical College of Cornell University to conduct research on "Characterizing 3'-UTR Biology as a Mechanism of Therapy Response in High-Risk Prostate Cancer." The research aims to advance understanding of disease mechanisms and potential therapeutic interventions for high-risk prostate cancer. The...
This federal Project Grant award, valued at $358,264.00, was issued on February 1, 2025 by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The award is funding research by Cornell University to target inflammatory pathways in breast cancer brain metastases for the treatment of edema and radiation necrosis using anti-VEGF ultrasmall particle therapy. The research aims to transform healthcare for military service members and the broader...
The Department of Defense's Defense Health Agency awarded a $1,759,295.00 Project Grant under the Military Health Services Research (MHSR) Program (CFDA 12.007) to the University of Nebraska Medical Center to measure and monitor the global disease burden of active duty women, including reproductive health. The project will be conducted from September 2024 to September 2026. The University of Nebraska Medical Center has subcontracted a portion of the work to the Henry M. Jackson Foundation for...
The Department of the Army Medical Command awarded a $762,750 Project Grant to Weill Medical College of Cornell University under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research on perk-driven stress responses that regulate dendritic cell function in ovarian cancer. Through June 2024, Weill Medical College will investigate how stress responses impact immune cell activity and how this relationship influences ovarian cancer progression....
This Project Grant award of $2,542,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by Weill Medical College of Cornell University to therapeutically target the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse and preclinical models of lung metastases. The research aims to transform healthcare for military service members and the broader public by advancing disease...
This federal Project Grant award of $1,008,313.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support advanced biomedical research by The Regents of the University of California, San Francisco (UCSF). The award, effective September 1, 2024 through August 31, 2027, will fund UCSF's research focused on transforming healthcare for military service members and the broader public. The research aims to advance disease prevention,...